Clinical trials: Ganglion
Parkinson Disease, Depression
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
- Conditions
- Parkinson Disease, Depression, Anxiety
- Trial name
- PDP1 (NCT04932434)
- Testing
- Psilocybin therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Joshua Woolley, MD, PhD
Parkinson's Disease
Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Apathy in Parkinson's Disease
The purpose of this research study is to attempt to treat apathy in Parkinson's disease (PD) using high-frequency repetitive transcranial magnetic stimulation (rTMS) of the brain and to investigate the patterns of brain…
- Trial name
- ReStore (NCT00955032)
- Testing
- High-Frequency Repetitive Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Parkinson Disease
Transcranial Magnetic Stimulation to Treat Parkinson's Disease
This study will look at the effects of transcranial magnetic stimulation (TMS) on symptoms of Parkinson's disease. TMS is a method of brain stimulation that may be able to change the activity of the nerve cells of the brain.
- Trial name
- NCT00753519
- Testing
- Real iTBS
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mark Hallett
Essential Tremor, Parkinson Disease
Pilot Study of the Felix System in Patients With Essential Tremor and Parkinson's Tremor
A prospective, open-label, multi-center pilot study designed to evaluate the safety and effectiveness of the Felix system in the relief of upper limb tremors in adults with essential tremor and Parkinson's disease.
- Trial name
- NCT05842434
- Testing
- Felix NeuroAI Wristband
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Fasikl Inc.
Dyskinesia, Levodopa Induced Dyskinesia
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
This is a multi-center, randomized, double-blind, placebo-controlled, 4-arm parallel group study to evaluate the tolerability and efficacy of each of three dose levels of ADS-5102 oral capsules, an extended release formulation of…
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia, Parkinson's Disease
- Trial name
- EASED (NCT01397422)
- Testing
- ADS-5102 (extended release amantadine HCl)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Parkinson's Disease, Constipation
Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation
This is a Phase 1/2a study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally-administered medication to relieve symptoms of constipation associated with Parkinson's Disease.
- Trial name
- RASMET (NCT03047629)
- Testing
- ENT-01
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- Enterin Inc.
Parkinson's Disease (PD)
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
The purpose of this study is to determine the rate and routes of excretion of OPC and the mass balance in urine, faeces and expired air.
- Trial name
- NCT02169427
- Testing
- OPC
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3
Varying oral doses of Varenicline (VCN), starting with very low doses, will be administered to participants with Parkinson's Disease (PD) or healthy controls without PD for several days.
- Trial name
- UdallP3 (NCT02933372)
- Testing
- Varenicline
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Obsessive-Compulsive Disorder, Autism Spectrum Disorder
Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders
This study will examine the effectiveness of riluzole for treating Obsessive-Compulsive Disorder in Youth, Including those with Autism Spectrum Disorders.
- Conditions
- Obsessive-Compulsive Disorder, Autism Spectrum Disorder, Autism, Asperger Disorder
- Trial name
- NCT00251303
- Testing
- Riluzole
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Mental Health (NIMH)
Parkinson Disease, Physical Activity
Neuroplasticity in Parkinson´s Disease After Training
This project aims to determine the effects of the HiBalance program on neuroplastic changes in people with mild to moderate Parkinson´s disease.
- Conditions
- Parkinson Disease, Physical Activity, Gait Disorders, Neurologic, Neural Degeneration
- Trial name
- BETA-PD (NCT03213873)
- Testing
- HiBalance, Speech and communication therapy
- Where
- Sweden
- Volunteers
- 95 people
- Sponsor
- Karolinska Institutet
Lewy Body Disease, Parkinson Disease
A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9…
- Trial name
- NCT04764669
- Testing
- E2027
- Where
- 14 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Eisai Inc.
Huntington Chorea
Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic movements.
- Trial name
- NCT05475483
- Testing
- SOM3355 200 mg capsules, SOM3355 300 mg capsules
- Where
- 23 sites in France, Germany and 5 more
- Volunteers
- 139 people
- Sponsor
- SOM Innovation Biotech SA
Huntington's Disease
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
The study is designed as a multi-site, prospective, 15-month longitudinal, cohort study measuring CSF mHTT in participants with early manifest Stage I or Stage II Huntington's Disease (HD).
- Trial name
- NCT03664804
- Testing
- No Study Drug was Administered in this Study
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an estimated incidence of 4.5-16/100,000 persons/year.
- Trial name
- BIPARKII (NCT01227655)
- Testing
- BIA 9-1067, Levodopa, Carbidopa
- Where
- Portugal
- Volunteers
- 427 people
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease, Sleep Disorder
Light Therapy for PD - Dose Selection
This study aims to determine the most effective dose of light therapy to improve sleep in people with Parkinson's Disease. Four groups of participants will receive bright-white or dim-red light therapy at different times…
- Conditions
- Parkinson Disease, Sleep Disorder, Fatigue
- Trial name
- NCT04291014
- Testing
- SunRay Light Boxes
- Where
- 25 sites in United States
- Volunteers
- 203 people
- Sponsor
- Massachusetts General Hospital
Parkinson Disease, Healthy Participants
A Study of TAK-071 in People With Parkinson Disease
It is hoped that TAK-071 will help people with Parkinson's disease to walk with better balance. The main aim of the study is to check if there is a difference in how participants walk after treatment with TAK-071.
- Trial name
- NCT04334317
- Testing
- TAK-071
- Where
- 21 sites in United States
- Volunteers
- 64 people
- Sponsor
- Takeda
Wilson Disease
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
This was a 24-month study to assess copper parameters in participants with Wilson disease (WD) treated with standard of care (SoC) medications.
- Trial name
- NCT02763215
- Testing
- Standard of Care Medications
- Where
- 10 sites in United States, Austria and 3 more
- Volunteers
- 64 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Parkinson's Disease
Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
The purpose of this research is to evaluate changes in cholinergic brain activity over time in subjects with Parkinson disease.
- Trial name
- NCT01106976
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Huntington's Disease
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
The primary objective of this study is to assess the efficacy of laquinimod as treatment in participants with HD after 52 weeks using the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS or TMS).
- Trial name
- LEGATO-HD (NCT02215616)
- Testing
- Laquinimod
- Where
- 53 sites in United States, Canada and 8 more
- Volunteers
- 352 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson's Disease (PD)
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.
- Trial name
- NCT02169440
- Testing
- BIA 9-1067, Warfarin
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.